title: Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism. The Venous Thromboembolism Study Group of the Spanish Society of Clinical Pharmacology.
abstract: 1. Thromboembolic disease (TED) is an important cause of in-hospital morbidity and mortality. Although different prophylactic approaches have been shown to be effective and cost-effective, surveys have suggested that they are underused. The aim of this study was to estimate the prevalence of use of TED prophylaxis in our hospitals. 2. All patients admitted on a specified day to the Internal Medicine and General Surgery wards of seven Spanish university hospitals were included in the study. They were identified cross-sectionally and followed up until discharge or for 15 days. Information about the following variables was collected: risk factors for venous thromboembolism, prophylactic measures used (if any), contraindications to the use of each specific drug or other prophylactic measure, and dosage schedule of the drug used, if any. 3. Nine hundred and thirty-nine patients (53% men) were studied. The most common risk factors for venous thromboembolism were: age > or = 40 years (802; 85%), major surgery (298; 32%), immobilization > or = 6 days (285; 30%), obesity (241; 26%), and cancer (202; 22%). 4. Prophylactic measures were used in 320 patients (34%). Of these, 297 (93%) received heparin, mainly as low molecular weight heparins (248, 78%); physical measures were rarely used. 5. Five hundred and eighty-three patients (62%) fulfilled criteria for moderate or high risk of venous thromboembolism; only 275 (47%) of them received any form of prophylaxis.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Servei de Farmacologia, CSU Vall d'Hebron, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Vallès
authors.forename: A
authors.initials: A
authors.lastname: Vallano
authors.forename: F
authors.initials: F
authors.lastname: Torres
authors.forename: J M
authors.initials: JM
authors.lastname: Arnau
authors.forename: J R
authors.initials: JR
authors.lastname: Laporte
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D004363:Drug Utilization; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007103:Immobilization / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D015999:Multivariate Analysis; D009369:Neoplasms / Q000150:complications; D009765:Obesity / Q000150:complications; D012307:Risk Factors; D013030:Spain; D013514:Surgical Procedures, Operative; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D006493:Heparin